{"id":12230,"date":"2023-10-31T11:45:00","date_gmt":"2023-10-31T03:45:00","guid":{"rendered":"https:\/\/flcube.com\/?p=12230"},"modified":"2024-11-12T11:56:48","modified_gmt":"2024-11-12T03:56:48","slug":"coheruss-loqtorzi-gains-fda-approval-for-nasopharyngeal-carcinoma-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=12230","title":{"rendered":"Coherus’s Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment"},"content":{"rendered":"\n

Coherus Biosciences (NASDAQ: CHRS<\/a>) executives held an investor conference call on October 30, 2023, to discuss the recent US FDA approval for Loqtorzi (toripalimab) as both a first- and second-line treatment for nasopharyngeal carcinoma (NPC). This approval, co-developed with Shanghai Junshi Biosciences Co., Ltd (HKG: 1877<\/a>; SHA: 688180<\/a>), marks a significant milestone as Loqtorzi becomes the first and only drug approved in the US specifically for NPC patients, setting a new standard of care.<\/p>\n\n\n\n

Commercial Launch and Market Strategy<\/strong>
The commercial launch of Loqtorzi is expected in early Q1 2024. Coherus plans to capture all 2,000 NPC patients diagnosed in the US each year, ensuring they begin using Loqtorzi “from day one.” With an estimated 40% of NPC patients in the US already using PD-1 inhibitors off-label, Coherus forecasts a rapid market penetration within 2-3 years.<\/p>\n\n\n\n

Pricing Strategy and CEO’s Stance<\/strong>
During the investor call, a question arose regarding potential discounts on Loqtorzi’s price compared to other PD-1 inhibitors. CEO Dennis Lanfear firmly ruled out significant discounts, emphasizing, \u201cThis is a branded product, with a unique indication, and we will not engage in heavily discounted prices for this product.\u201d The exact price point will be revealed upon market launch next year.<\/p>\n\n\n\n

Development Strategy and Future Pipeline<\/strong>
Loqtorzi will serve as the cornerstone of Coherus\u2019s future oncology strategy and will be used alongside other pipeline candidates, particularly those from Coherus\u2019s acquisition of Surface Oncology in September. The approval allows Coherus to advance to the next stage of its development strategy, which includes pairing Loqtorzi with Cazdozokitug (SRF388), an IL-27 antibody, and CHS-114, a CCR8-targeted antibody. Coherus is also exploring new external co-development partnerships involving other modalities such as bispecifics and T-cell engagers.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Coherus Biosciences (NASDAQ: CHRS) executives held an investor conference call on October 30, 2023, to…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[613,899,296,40,1307,18,900],"class_list":["post-12230","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-coherus-biosciences","tag-hkg-1877","tag-junshi-biosciences","tag-market-launch","tag-nasdaq-chrs","tag-pd-1-l1","tag-sha-688180"],"yoast_head":"\nCoherus's Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Coherus Biosciences (NASDAQ: CHRS) executives held an investor conference call on October 30, 2023, to discuss the recent US FDA approval for Loqtorzi (toripalimab) as both a first- and second-line treatment for nasopharyngeal carcinoma (NPC). This approval, co-developed with Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), marks a significant milestone as Loqtorzi becomes the first and only drug approved in the US specifically for NPC patients, setting a new standard of care.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=12230\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Coherus's Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=12230\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-31T03:45:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-12T03:56:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12230#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12230\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Coherus’s Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment\",\"datePublished\":\"2023-10-31T03:45:00+00:00\",\"dateModified\":\"2024-11-12T03:56:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12230\"},\"wordCount\":293,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Coherus Biosciences\",\"HKG: 1877\",\"Junshi Biosciences\",\"Market launch\",\"NASDAQ: CHRS\",\"PD-1\\\/L1\",\"SHA: 688180\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12230#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12230\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=12230\",\"name\":\"Coherus's Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-10-31T03:45:00+00:00\",\"dateModified\":\"2024-11-12T03:56:48+00:00\",\"description\":\"Coherus Biosciences (NASDAQ: CHRS) executives held an investor conference call on October 30, 2023, to discuss the recent US FDA approval for Loqtorzi (toripalimab) as both a first- and second-line treatment for nasopharyngeal carcinoma (NPC). This approval, co-developed with Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), marks a significant milestone as Loqtorzi becomes the first and only drug approved in the US specifically for NPC patients, setting a new standard of care.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12230#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12230\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12230#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Coherus’s Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Coherus's Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment - Insight, China's Pharmaceutical Industry","description":"Coherus Biosciences (NASDAQ: CHRS) executives held an investor conference call on October 30, 2023, to discuss the recent US FDA approval for Loqtorzi (toripalimab) as both a first- and second-line treatment for nasopharyngeal carcinoma (NPC). This approval, co-developed with Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), marks a significant milestone as Loqtorzi becomes the first and only drug approved in the US specifically for NPC patients, setting a new standard of care.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=12230","og_locale":"en_US","og_type":"article","og_title":"Coherus's Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=12230","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-10-31T03:45:00+00:00","article_modified_time":"2024-11-12T03:56:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=12230#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=12230"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Coherus’s Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment","datePublished":"2023-10-31T03:45:00+00:00","dateModified":"2024-11-12T03:56:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=12230"},"wordCount":293,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Coherus Biosciences","HKG: 1877","Junshi Biosciences","Market launch","NASDAQ: CHRS","PD-1\/L1","SHA: 688180"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=12230#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=12230","url":"https:\/\/flcube.com\/?p=12230","name":"Coherus's Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-10-31T03:45:00+00:00","dateModified":"2024-11-12T03:56:48+00:00","description":"Coherus Biosciences (NASDAQ: CHRS) executives held an investor conference call on October 30, 2023, to discuss the recent US FDA approval for Loqtorzi (toripalimab) as both a first- and second-line treatment for nasopharyngeal carcinoma (NPC). This approval, co-developed with Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), marks a significant milestone as Loqtorzi becomes the first and only drug approved in the US specifically for NPC patients, setting a new standard of care.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=12230#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=12230"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=12230#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Coherus’s Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12230"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12230\/revisions"}],"predecessor-version":[{"id":12233,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12230\/revisions\/12233"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}